Insmed Incorporated (INSM)
After hours:
| Previous Close | 25.81 |
| Open | 25.43 |
| Bid | 24.91 x 400 |
| Ask | 24.94 x 600 |
| Day's Range | 24.82 - 25.43 |
| 52 Week Range | 18.09 - 32.00 |
| Volume | |
| Avg. Volume | 1,740,729 |
| Market Cap | 3.702B |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024.
- PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- PR Newswire
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego. Presentations will include late-breaking microbiologic data from the ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) in patien
